| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-27149 | |||
| BSA Free | NB100-56566SS | |||
| Azide and BSA Free | NBP2-27149SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NB100-56726 | |||
| BSA Free | NB100-56722SS | |||
| Azide and BSA Free | NB100-56726SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-24893 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-24787SS | |||
| Azide and BSA Free | NBP2-80981 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-1071SS | |||
| Azide and BSA Free | NBP2-80642 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-74396SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-179SS | |||
![Dual RNAscope ISH-IHC: TLR4 Antibody (76B357.1) [NB100-56566] - FFPE tissue sections of human tonsil were probed for TLR4 mRNA (ACD RNAScope Probe, ACD catalog # 311281; Fast Red chromogen, ACD catalog # 322750). Adjacent tissue section was processed for immunohistochemistry using Mouse Monoclonal (Novus Biologicals catalog # NB100-56566) at 5ug/mL with 1 hour incubation at room temperature followed by incubation with anti-mouse IgG VisUCyte HRP Polymer Antibody (Catalog # VC001) and DAB chromogen (yellow-brown). Tissue was counterstained with hematoxylin (blue). Specific staining was localized to lymphocytes.](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Dual-RNAscope-ISH-IHC-NB100-56566-img0036.jpg "<b>Orthogonal Strategies Validation. </b>Dual RNAscope ISH-IHC: TLR4 Antibody (76B357.1) [NB100-56566] - FFPE tissue sections of human tonsil were probed for TLR4 mRNA (ACD RNAScope Probe, ACD catalog # 311281; Fast Red chromogen, ACD catalog # 322750). Adjacent tissue section was processed for immunohistochemistry using Mouse Monoclonal (Novus Biologicals catalog # NB100-56566) at 5ug/mL with 1 hour incubation at room temperature followed by incubation with anti-mouse IgG VisUCyte HRP Polymer Antibody (Catalog # VC001) and DAB chromogen (yellow-brown). Tissue was counterstained with hematoxylin (blue). Specific staining was localized to lymphocytes.")
![<b>Orthogonal Strategies Validation. </b>Flow Cytometry: TLR4 Antibody (76B357.1) [NB100-56566] - Analysis using the Alexa Fluor (R) 647 conjugate of NBP2-27149. TLR4 expression on monocytes from human peripheral blood. PBMC were stained in a 2 color flow test, with CD14 PE version of this antibody and 1 ug of either isotype control (left) or TLR4-Alexa Fluor 647 (right). PPI negative, CD14+ cells were gated for analysis.](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Flow-Cytometry-NB100-56566-img0024.jpg)
![Immunohistochemistry: TLR4 Antibody (76B357.1) [NB100-56566] - Pericryptal Myofibroblasts are Responsible for Increased TLR4 Expression in a Subset of CRCs. Double-stained immunofluorescence for TLR4 (green) and vimentin (red) in normal (I), adenoma (II), and colon adenocarcinoma (III) (10x). In the stromal compartment of CRCs, immunofluorescent staining for TLR4 localized to the pericryptal myofibroblasts in a subset of samples. Image collected and cropped by CiteAb from the following publication (//www.jeccr.com/content/33/1/45), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Immunohistochemistry-NB100-56566-img0040.jpg)
![Western Blot: TLR4 Antibody (76B357.1) [NB100-56566] - Analysis using 2 ug/mL on (A) human intestine and 6 ug/mL on (B) mouse intestine and (C) rat intestine lysate.](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Western-Blot-NB100-56566-img0018.jpg)
![Immunohistochemistry: TLR4 Antibody (76B357.1) [NB100-56566] - Pericryptal Myofibroblasts are Responsible for Increased TLR4 Expression in a Subset of CRCs. IHC staining of colon adenocarcinoma for TLR4, vimentin, and alpha-SMA (40x). Staining co-localizes to the pericryptal space, confirming the signal arises from pericryptal myofibroblasts. Image collected and cropped by CiteAb from the following publication (//www.jeccr.com/content/33/1/45), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Immunohistochemistry-NB100-56566-img0041.jpg)
![Flow (Intracellular): TLR4 Antibody (76B357.1) [NB100-56566] - Analysis using PE conjugate of NBP2-27149. An intracellular stain was performed on Jurkat cells with TLR4 antibody (76B357.1) NBP2-27149PE (blue) and an isotype control MAB004 (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to phycoerythrin.](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Flow-Intracellular-NB100-56566-img0025.jpg)
![Immunocytochemistry/Immunofluorescence: TLR4 Antibody (76B357.1) [NB100-56566] - RH-30 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-TLR4 Antibody (76B357.1) NB100-56566 at 1 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Immunocytochemistry-Immunofluorescence-NB100-56566-img0042.jpg)
![Immunohistochemistry: TLR4 Antibody (76B357.1) [NB100-56566] - Immunofluorescent staining of TMAs. Representative tissue cores from normal (I), adenomatous polyps (II), and CRC (III and IV) are shown. Image collected and cropped by CiteAb from the following publication (//www.jeccr.com/content/33/1/45), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Immunohistochemistry-NB100-56566-img0037.jpg)
![Immunohistochemistry-Paraffin: TLR4 Antibody (76B357.1) [NB100-56566] - Analysis of rat salivary gland tissue section at 1:100 dilution. The antibody generated a membrane-cytoplasmic staining in the tissue with stronger signal in ductal epithelial cells.](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Immunohistochemistry-Paraffin-NB100-56566-img0015.jpg)
![Immunohistochemistry-Paraffin: TLR4 Antibody (76B357.1) [NB100-56566] - Tissue section of normal human skin stained with antibody at 5 ug/mL. Membrane-cytoplasmic immunopositivity of TLR4 was primarily observed in the pigmented basel cells and the adjacent keratinocytes in the epidermal layer.](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Immunohistochemistry-Paraffin-NB100-56566-img0013.jpg)
![Flow Cytometry: TLR4 Antibody (76B357.1) [NB100-56566] - An intracellular stain was performed on RH30 cells with TLR4 Antibody (76B357.1) NB100-56566 (blue) and a matched mouse IgG2b Kappa isotype control (orange) MAB004. Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Flow-Cytometry-NB100-56566-img0045.jpg)
![Immunohistochemistry-Paraffin: TLR4 Antibody (76B357.1) [NB100-56566] - Human skin stained with at 5 ug/mL, peroxidase-conjugate and DAB chromogen. Staining of formalin-fixed tissues is enhanced by boiling tissue sections in 10 mM sodium citrate buffer, pH 6.0 for 10-20 min followed by cooling at RT for 20 min.](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Immunohistochemistry-Paraffin-NB100-56566-img0007.jpg)
![Immunohistochemistry-Paraffin: TLR4 Antibody (76B357.1) [NB100-56566] - Analysis of TLR4 in FFPE human colon tissue using an isotype control (top) and NB100-56566 (bottom) at 5 ug/mL.](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Immunohistochemistry-Paraffin-NB100-56566-img0016.jpg)
![Immunohistochemistry-Paraffin: TLR4 Antibody (76B357.1) [NB100-56566] - Human testis tissue stained with antibody at 5 ug/mL.](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Immunohistochemistry-Paraffin-NB100-56566-img0017.jpg)
![Immunohistochemistry-Frozen: TLR4 Antibody (76B357.1) [NB100-56566] - This image is TLR4(green) and nucleus(blue) at area postrema of the adult male mouse brain, x20 magnification. Primary antibody diluted 1:500. IHC-Fr image submitted by a verified customer review.](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Immunohistochemistry-Frozen-NB100-56566-img0032.jpg)
![Flow Cytometry: TLR4 Antibody (76B357.1) [NB100-56566] - Analysis of formaldehyde fixed THP-1 cells (human monocytic leukemia cells) using 2 ug/10^6 cells TLR4 antibody (clone 76B357.1) with detection employing a donkey anti-mouse IgG (H+L) cross adsorbed secondary antibody, (DyLight 488 conjugated). Isotype control samples incubated with mouse IgG2b isotype control antibody were processed in parallal under the same assay conditions.](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Flow-Cytometry-NB100-56566-img0031.jpg)
![Flow Cytometry: TLR4 Antibody (76B357.1) [NB100-56566] - An intracellular stain was performed on Jurkat cells with TLR4 Antibody (76B357.1) NB100-56566 (blue) and a matched mouse IgG2b Kappa isotype control (orange) MAB004. Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Flow-Cytometry-NB100-56566-img0043.jpg)
![Flow Cytometry: TLR4 Antibody (76B357.1) [NB100-56566] - An intracellular stain was performed on Raw264.7 cells with TLR4 Antibody (76B357.1) NB100-56566 (blue) and a matched mouse IgG2b Kappa isotype control (orange) MAB004. Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Flow-Cytometry-NB100-56566-img0044.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Increased toll‐like receptor 4 (TLR4) expression in the myocardium of chronic heart failure (CHF) rats. (A) TLR4 mRNA levels in infarct & remote myocardium of sham & CHF rats (n = 6/group). (B) Representative Western blot images & (C) quantification of TLR4 proteins in infarct & remote myocardium of sham & CHF rats (n = 4/group). (D) Representative immunohistochemistry images of heart sections stained with TLR4 (green) & CD45 (red). The yellow box indicates the enlarged area shown on the right (data are means ± SD, *P < 0.05, **P < 0.01 versus respective sham). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26290459), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-31020241539724.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Regulation of FOXC1 on TLR3/4 expression in mice subjected to myocardial ischaemia (MI). The siRNA against FOXC1 (si‐FOXC1) or FOXC1 adenovirus (Ad‐FOXC1) was injected into the left ventricle just after LAD ligation to generate FOXC1 knockdown (A) or FOXC1 overexpression (B), & the negative control (NC) siRNA & Ad‐GFP served as control, respectively. The mRNA (upper panel) & protein (middle & lower panel) levels of TLR3/4 were determined after 2 wk. Data are means ± SEM aP < .05, AP < .01 vs respective MI Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31517441), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-310202415345314.jpg)
![Immunohistochemistry: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Representative images of immunohistochemical staining of pancreatic adenocarcinoma upregulated factor (PAUF) & toll-like receptor 4 (TLR4) in human ovarian cancer specimens. The top row (A,B) represents normal ovarian tissue, middle row (C,D) shows immunoreactivity of ovarian carcinomas & the bottom row (E,F) indicates immunonegativity of ovarian caricinoma. The stromal cells of normal ovarian tissue show immunonegativity for PAUF & TLR4. The scale bar represents 100 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30111860), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-310202415293340.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Increased toll‐like receptor 4 (TLR4) expression in the surviving cardiomyocytes of chronic heart failure (CHF) rats. (A) Representative immunofluorescent images of TLR4 in cardiomyocytes isolated from sham & CHF rats. (B) TLR4 mRNA levels in cardiomyocytes isolated from sham & CHF rats. (C) Representative Western blot images & (D) quantification of TLR4 proteins in cardiomyocytes isolated from sham & CHF rats (data are means ± SD, n = 6/group, **P < 0.01 versus sham). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26290459), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-310202415175298.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Up‐regulation of FOXC1 & TLR3/4 protein levels under myocardial ischaemia. Representative Western blot images & quantitative data for FOXC1, TLR3 & TLR4 proteins in ischaemia models of mice (A), H9c2 cells (B) & NRVMs (C) are shown herein. Validation data of the antibodies for TLR3 & TLR4 are shown in Figure S1. Data are means ± SEM. n = ~4‐5/group. P values from the one‐way ANOVAs: 0.018 (TLR3 protein in mice), .002 (TLR4 protein in mice) & 0.006 (FOXC1 protein in mice). aP < .05, AP < .01 vs control Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31517441), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-31020241534393.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - (a) Cell viability of MM cells exposed to increasing doses of LPS for 24 h. (b) Immunoblotting analysis of TLR4 protein expression levels in H929 & L363 cell lines after incubation with various LPS concentrations. Probing with beta -ACTIN was used as total protein loading reference. (c) Flow cytometry analysis for TLR4 expression of MM cell lines before & after exposure to 1 μg/ml LPS for 24 h. (d) Cell viability of MM cell lines pre-treated with 0.5 μg/ml TLR4 inhibitor for 24 h before stimulation with LPS for 24 h. (e) Cell vViability of H929 & JJN3 cell lines exposed to increasing concentrations of TLR4 inhibitor for 48 h. beta -ACTIN probing was used as reference for total protein input. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30824741), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-310202415304291.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Regulation of FOXC1 on TLR3/4 expression in mice subjected to myocardial ischaemia (MI). The siRNA against FOXC1 (si‐FOXC1) or FOXC1 adenovirus (Ad‐FOXC1) was injected into the left ventricle just after LAD ligation to generate FOXC1 knockdown (A) or FOXC1 overexpression (B), & the negative control (NC) siRNA & Ad‐GFP served as control, respectively. The mRNA (upper panel) & protein (middle & lower panel) levels of TLR3/4 were determined after 2 wk. Data are means ± SEM aP < .05, AP < .01 vs respective MI Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31517441), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-310202415371989.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Up‐regulation of FOXC1 & TLR3/4 protein levels under myocardial ischaemia. Representative Western blot images & quantitative data for FOXC1, TLR3 & TLR4 proteins in ischaemia models of mice (A), H9c2 cells (B) & NRVMs (C) are shown herein. Validation data of the antibodies for TLR3 & TLR4 are shown in Figure S1. Data are means ± SEM. n = ~4‐5/group. P values from the one‐way ANOVAs: 0.018 (TLR3 protein in mice), .002 (TLR4 protein in mice) & 0.006 (FOXC1 protein in mice). aP < .05, AP < .01 vs control Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31517441), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-310202415291964.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Up‐regulation of FOXC1 & TLR3/4 protein levels under myocardial ischaemia. Representative Western blot images & quantitative data for FOXC1, TLR3 & TLR4 proteins in ischaemia models of mice (A), H9c2 cells (B) & NRVMs (C) are shown herein. Validation data of the antibodies for TLR3 & TLR4 are shown in Figure S1. Data are means ± SEM. n = ~4‐5/group. P values from the one‐way ANOVAs: 0.018 (TLR3 protein in mice), .002 (TLR4 protein in mice) & 0.006 (FOXC1 protein in mice). aP < .05, AP < .01 vs control Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31517441), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-31020241530423.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - TLR4 mRNA (a1) & protein (a2) expression in MM cell lines. (b) TLR4 mRNA expression of 16 CD138+ selected MM patients as determined by PCR & agarose gel electrophoresis. Probing with beta -ACTIN was used as total protein loading reference, whereas beta -ACTIN gene expression was used as reference for RNA input. beta -ACTIN probing & beta -ACTIN mRNA expression were used as reference for total protein & mRNA input, respectively. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30824741), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-31020241534332.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Regulation of FOXC1 on TLR expression. H9c2 cells were transfected with adenovirus or siRNA to overexpress or knock down FoxC1, with GFP adenovirus (Ad‐GFP) & negative control (NC) siRNA serving as control, respectively. A, FoxC1 overexpression increased Tlr3/4 mRNA & protein levels, under both control & ischaemic conditions. P values from the one‐way ANOVAs: <.001 (TLR3 mRNA), .002 (TLR4 mRNA), <.001 (FOXC1 mRNA), <.001 (TLR3 protein), <0.001 (TLR4 protein) & <.001 (FOXC1 protein). B, FoxC1 knockdown decreased Tlr3/4 mRNA & protein levels. P values from the one‐way ANOVAs: .001 (TLR3 mRNA), <.001 (TLR4 mRNA), <.001 (FOXC1 mRNA), .002 (TLR3 protein), <.001 (TLR4 protein) & <.001 (FOXC1 protein). C, FoxC1 overexpression up‐regulated the mRNA expression of multiple Tlr subtypes. P values from the one‐way ANOVAs: .022 (TLR1 mRNA), .047 (TLR2 mRNA), .002 (TLR3 mRNA), .013 (TLR4 mRNA), .039 (TLR5 mRNA), .003 (TLR6 mRNA), .203 (TLR7 mRNA), .078 (TLR8 mRNA) & .009 (TLR9 mRNA). Data are means ± SEM of 4 independent experiments. aP < .05, AP < .01 vs. control; bP < .05, BP < 0.01 vs. ischaemia Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31517441), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-31020241683915.jpg)
![Immunocytochemistry/ Immunofluorescence: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Immunofluorescent staining of TMAs. A) Low power (10x) view of NCI TMA slide stained for TLR4 (green), intestinal epithelium/pan-cytokeratin (red), & nucleus/DAPI (blue). B) Representative tissue cores from normal (I), adenomatous polyps (II), & CRC (III & IV) are shown. C & D) TLR4 staining score by tissue type & tissue compartment (stroma vs epithelium) are shown. C) TLR4 staining in the tumor stroma had a significantly higher average intensity score for stages 3 & 4 CRC when compared to stage 1. D) TLR4 staining in the tumor epithelium had a significantly higher average intensity score for stages 2 & 3 when compared to stage 1. E) TLR4 staining by compartment broken down by stage (controlling for grade) & grade (controlling for stage). Image collected & cropped by CiteAb from the following publication (//jeccr.biomedcentral.com/articles/10.1186/1756-9966-33-45), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-310202415525244.jpg)
![Immunocytochemistry/ Immunofluorescence: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Immunofluorescent staining of TMAs. A) Low power (10x) view of NCI TMA slide stained for TLR4 (green), intestinal epithelium/pan-cytokeratin (red), & nucleus/DAPI (blue). B) Representative tissue cores from normal (I), adenomatous polyps (II), & CRC (III & IV) are shown. C & D) TLR4 staining score by tissue type & tissue compartment (stroma vs epithelium) are shown. C) TLR4 staining in the tumor stroma had a significantly higher average intensity score for stages 3 & 4 CRC when compared to stage 1. D) TLR4 staining in the tumor epithelium had a significantly higher average intensity score for stages 2 & 3 when compared to stage 1. E) TLR4 staining by compartment broken down by stage (controlling for grade) & grade (controlling for stage). Image collected & cropped by CiteAb from the following publication (//jeccr.biomedcentral.com/articles/10.1186/1756-9966-33-45), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-31020241553739.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Effect of Cucumis sativus L. extract (CSE) on LPS induced TLR4 expression. a Expression of TLR4 mRNA in pAECs treated with LPS (10 μg/ml) for different time (1, 7, 24 h) in the presence or absence of increasing doses of CSE (0.02; 0.2; 2 mg/ml). mRNA expression of TLR4 is determined by quantitative PCR; relative expression was calculated as fold of change in respect to the control cells & error bar represents the range of relative expression. Different letters above the bars indicate significant differences. b Representative Western Blot of TLR4 & relative housekeeping alpha -tubulin were reported. c Expression of TLR4 protein in pAECs treated with LPS (10 μg/ml) in the presence or absence of increasing doses CSE (0.02; 0.2; 2 mg/ml); data shown are representative of at least three independent experiments & represent the mean ± SEM. Different letters above the bars indicate significant differences (p < 0.05 ANOVA post hoc Tukey’s test) Image collected & cropped by CiteAb from the following publication (//bmccomplementalternmed.biomedcentral.com/articles/10.1186/s12906-018-2254-1), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-31020241553730.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Activation receptors are shed during intrinsic repair. (A) BMDM were unchallenged (control) or challenged with 500 HU/mL SLO WT, PFO or an equivalent mass of SLO ML for 10 min at 37 °C & centrifuged at 2000 × g for 5 min to yield cell pellet (C). Supernatants were spun at 100,000xg for 40 min at 4 °C to collect the high speed supernatant (S) & microvesicle pellet (M). Samples were solubilized at 95 °C in SDS-sample buffer, resolved by SDS-PAGE & transferred to nitrocellulose. Portions of the blot were probed with 6D11 anti-SLO, anti-IFN gamma R1, 4B4F12 anti-CD14, 76B357.1 anti-TLR4, O91B8 anti-MyD88, 1H4B01 anti-Trif, EPR4477 anti-Alkaline Phosphatase, MANLAC-4A7 anti-Lamin A/C, & AC-15 anti-beta -Actin antibodies followed by relevant secondary antibodies & ECL. Full-length blots are presented in Supplementary Figure S1. (B) BMDM were challenged with 500 HU/mL SLO WT or SLO N402C, SLO ML at equivalent mass to SLO WT, or SLO N402E at equivalent mass to SLO N402C for 10 min. Cell pellets (C), high speed supernatants (S) & microvesicles (M) were isolated as in (A) & probed with 6D11 anti-Streptolysin O, 76B357.1 anti-TLR4, O91B8 anti-MyD88, 1H4B01 anti-Trif, EPR4477 anti-Alkaline Phosphatase, MANLAC-4A7 anti-Lamin A/C, & AC-15 anti-beta -Actin antibodies. Full-length blots are presented in Supplementary Figure S2. The blots are representative of at least 3 independent experiments. Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-018-24955-2), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-310202415535180.jpg)
![Immunocytochemistry/ Immunofluorescence: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Pericryptal Myofibroblasts are Responsible for Increased TLR4 Expression in a Subset of CRCs. A) CRCs were separated into two groups representing low- & high- stromal expression of TLR4 by IHC staining. In normal tissue, stromal TLR4 expression is mainly due to macrophages (Green: TLR4, Red: CD68, Merge: TLR4 + CD68 + DAPI (blue)). Conversely, in CRCs increased vimentin & decreased CD68 staining in the pericryptal space confirm that this signal was due to pericryptal myofibroblasts & not related to tumor-associated macrophages. B) Double-stained immunofluorescence for TLR4 (green) & vimentin (red) in normal (I), adenoma (II), & colon adenocarcinoma (III) (10×). In the stromal compartment of CRCs, immunofluorescent staining for TLR4 localized to the pericryptal myofibroblasts in a subset of samples. C) IHC staining of colon adenocarcinoma for TLR4, vimentin, & alpha -SMA (40×). Staining co-localizes to the pericryptal space, confirming the signal arises from pericryptal myofibroblasts. D, E, & F) An increase in IHC staining for alpha -SMA & vimentin was noted in CRCs when compared to normal or low grade dysplasia. A decrease in staining for CD68 positive macrophages was observed with higher degrees of dysplasia. Image collected & cropped by CiteAb from the following publication (//jeccr.biomedcentral.com/articles/10.1186/1756-9966-33-45), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-31020241553724.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - (a1) Q-PCR assay of TLR4 mRNA expression levels after transfecting JJN3 cell line with TLR4 RNAi oligonucleotides or a non-targeting pool (siCtrl) for 48 h. (a2) Representative immunoblotting analyses of protein samples probed with an antibody against TLR4 after TLR4 RNAi for 48 h. (b1) % cell viability & (b2) % proliferation of JJN3 cells after TLR4 RNAi for 48 h. (c,d1) Q-PCR expression analyses of TLR4 mRNA expression levels after transfecting H929 (c) & U266 (d1) cell lines with the pCMV6-TLR4 construct or a pCMV6 empty vector for 48 h. (d2) Immunobloting analyses of U266 cells transfected with pCMV6-TLR4 or pCMV6 vector for 48 h; protein samples were probed with an antibody against TLR4. (e1) % cell viability & (e2) % proliferation of H929 & U266 cells after transfection with the pCMV6-TLR4 construct or with the empty pCMV6 vector for 48 h. beta -ACTIN probing & beta -ACTIN mRNA expression were used as reference for total protein & mRNA input, respectively. Cells transfected with the pCMV6-TLR4 construct are labelled as TLR4 OE (TLR4 overexpression), whereas cells transfected with the pCMV6 empty vector are labelled as Con (control). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30824741), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-31020241682147.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Regulation of FOXC1 on TLR expression. H9c2 cells were transfected with adenovirus or siRNA to overexpress or knock down FoxC1, with GFP adenovirus (Ad‐GFP) & negative control (NC) siRNA serving as control, respectively. A, FoxC1 overexpression increased Tlr3/4 mRNA & protein levels, under both control & ischaemic conditions. P values from the one‐way ANOVAs: <.001 (TLR3 mRNA), .002 (TLR4 mRNA), <.001 (FOXC1 mRNA), <.001 (TLR3 protein), <0.001 (TLR4 protein) & <.001 (FOXC1 protein). B, FoxC1 knockdown decreased Tlr3/4 mRNA & protein levels. P values from the one‐way ANOVAs: .001 (TLR3 mRNA), <.001 (TLR4 mRNA), <.001 (FOXC1 mRNA), .002 (TLR3 protein), <.001 (TLR4 protein) & <.001 (FOXC1 protein). C, FoxC1 overexpression up‐regulated the mRNA expression of multiple Tlr subtypes. P values from the one‐way ANOVAs: .022 (TLR1 mRNA), .047 (TLR2 mRNA), .002 (TLR3 mRNA), .013 (TLR4 mRNA), .039 (TLR5 mRNA), .003 (TLR6 mRNA), .203 (TLR7 mRNA), .078 (TLR8 mRNA) & .009 (TLR9 mRNA). Data are means ± SEM of 4 independent experiments. aP < .05, AP < .01 vs. control; bP < .05, BP < 0.01 vs. ischaemia Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31517441), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-31020241552396.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Dasatinib affects TLR4 signaling to regulate LPS-induced proinflammatory cytokine levels in BV2 microglial cells. a BV2 microglial cells were pretreated with TAK-242 (a TLR4 receptor inhibitor, 500 nM) or vehicle (1% DMSO) for 30 min, treated with dasatinib (250 nM) or vehicle (1% DMSO) for 30 min, & treated with LPS (1 μg/ml) or PBS for 5 h. The mRNA levels of COX-2 & IL-6 were analyzed by RT-PCR. b, c Quantification of the data in a (COX-2: con, n = 10; LPS, n = 10; dasatinib+LPS, n = 10; TAK-242+LPS, n = 10; TAK-242+dasatinib+LPS, n = 10; & IL-6: con, n = 14; LPS, n = 14; dasatinib+LPS, n = 14; TAK-242+LPS, n = 14; TAK-242+ dasatinib+LPS, n = 14). d BV2 microglial cells were treated with dasatinib (250 nM) or vehicle (1% DMSO) for 30 min followed by LPS (1 μg/ml) or PBS for 5.5 h, & cell surface biotinylation was conducted. e, f Quantification of the data in d (Surface TLR4: con, n = 11; LPS, n = 11; dasatinib+LPS, n = 11; Total TLR4: con, n = 16; LPS, n = 16; dasatinib+LPS, n = 16). One-way ANOVA with Tukey’s post hoc test was used to analyze significant differences. **p < 0.01, ***p < 0.001 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31655606), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-3102024168390.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - (a1) Q-PCR assay of TLR4 mRNA expression levels after transfecting JJN3 cell line with TLR4 RNAi oligonucleotides or a non-targeting pool (siCtrl) for 48 h. (a2) Representative immunoblotting analyses of protein samples probed with an antibody against TLR4 after TLR4 RNAi for 48 h. (b1) % cell viability & (b2) % proliferation of JJN3 cells after TLR4 RNAi for 48 h. (c,d1) Q-PCR expression analyses of TLR4 mRNA expression levels after transfecting H929 (c) & U266 (d1) cell lines with the pCMV6-TLR4 construct or a pCMV6 empty vector for 48 h. (d2) Immunobloting analyses of U266 cells transfected with pCMV6-TLR4 or pCMV6 vector for 48 h; protein samples were probed with an antibody against TLR4. (e1) % cell viability & (e2) % proliferation of H929 & U266 cells after transfection with the pCMV6-TLR4 construct or with the empty pCMV6 vector for 48 h. beta -ACTIN probing & beta -ACTIN mRNA expression were used as reference for total protein & mRNA input, respectively. Cells transfected with the pCMV6-TLR4 construct are labelled as TLR4 OE (TLR4 overexpression), whereas cells transfected with the pCMV6 empty vector are labelled as Con (control). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30824741), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-310202415532051.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - TLR4 expression in pVW-MSCs cultured with or without LPS (10 μg/ml) for 1 & 4 h & after additional 24 h of recovery after LPS removal (4hR). a: flow cytometry analysis were performed in not fixed & not permeabilized cells for TLR4 surface expression determination (TLR4: Surface) & in fixed & permeabilized cells to measure the overall TLR4 amount (TLR4: Total). Red histograms: stained cells; blue histograms: control cells. b: representative Western Blot of TLR4 & housekeeping beta -tubulin & relative quantification were presented. c: representative images of TLR4 immunostaining of pVW-MSCs cultured with or without LPS (10 μg/ml) for 4 h. pVW-MSCs nuclei were stained with Hoechst 33258 (blue). Scale bar = 10 μm. Data shown represent the mean ± SD of three biological replicates, each experiment is repeated three times. Data were analysed using one-way ANOVA followed by the Tukey’s post hoc comparison test. Different letters above the bars indicate significant differences (p < 0.05). (AU = Arbitrary Units) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31029157), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-3102024155457.jpg)
![Flow Cytometry: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - TLR4 expression in pVW-MSCs cultured with or without LPS (10 μg/ml) for 1 & 4 h & after additional 24 h of recovery after LPS removal (4hR). a: flow cytometry analysis were performed in not fixed & not permeabilized cells for TLR4 surface expression determination (TLR4: Surface) & in fixed & permeabilized cells to measure the overall TLR4 amount (TLR4: Total). Red histograms: stained cells; blue histograms: control cells. b: representative Western Blot of TLR4 & housekeeping beta -tubulin & relative quantification were presented. c: representative images of TLR4 immunostaining of pVW-MSCs cultured with or without LPS (10 μg/ml) for 4 h. pVW-MSCs nuclei were stained with Hoechst 33258 (blue). Scale bar = 10 μm. Data shown represent the mean ± SD of three biological replicates, each experiment is repeated three times. Data were analysed using one-way ANOVA followed by the Tukey’s post hoc comparison test. Different letters above the bars indicate significant differences (p < 0.05). (AU = Arbitrary Units) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31029157), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-31020241552524.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Toll‐like receptor 4 (TLR4)‐shRNA lentivirus reduced myocardial inflammation & improved heart function after myocardial infarction (MI). The rats received intra‐myocardial injection of normal saline (NS), control‐shRNA lentivirus or TLR4‐shRNA lentivirus (1 × 109 TU/ml, 100 μl/heart) just after left anterior descending coronary artery (LAD) ligation or sham operation. All examinations were performed after 4 weeks of MI. (A) Expression of green fluorescent protein (GFP; green), the marker gene carried by TLR4‐shRNA lentivirus, in the myocardium. The nuclei were counter‐stained with Hoechst 33258 (blue). (B) Representative Western blot images & quantification of TLR4 proteins in sham & chronic heart failure (CHF) myocardium. (C) tumour necrosis factor (TNF)‐ alpha & interleukin (IL)‐6 protein contents in infarct & remote myocardium. (D) Representative images of Masson's trichrome staining (upper panel) & quantification (lower panel) of post‐infarct failing hearts, showing that TLR4‐shRNA lentivirus reduced cardiac fibrosis. Cross‐sections were cut at the midhorizontal plane of the fixed paraffin‐embedded heart, & stained with Masson's trichrome reagents. (E) Infarct size of post‐infarct failing hearts. (F) Fractional shortening (%) of the left ventricle (data are means ± SD, n = 4/group, aP < 0.05, AP < 0.01 versus respective sham‐NS; BP < 0.01 versus respective CHF‐NS). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26290459), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-310202415523925.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - ALWPs significantly reduced LPS-induced cell-surface levels of TLR4. (A) BV2 microglial cells were pretreated with TAK-242 (a TLR4 inhibitor, 500 nM) for 30 min, followed by treatment with ALWPs (500 μg/ml) or PBS for 30 min & finally LPS (1 μg/ml) or PBS for 5 h. Total RNA was isolated, & IL-1 beta mRNA levels were measured by RT-PCR. (B) Quantification of the data from (A) (con, n = 20; LPS, n = 20; ALWPs + LPS, n = 20; TAK-242 + LPS, n = 20; TAK-242 + ALWPs + LPS, n = 20). (C) BV2 microglial cells were pretreated with ALWPs (500 μg/ml) or PBS for 30 min, followed by treatment with LPS (1 μg/ml) or PBS for 5.5 h. Cell-surface biotinylation was then conducted with a TLR4 antibody recognizing the N-terminal region of TLR4. (D) Quantification of the data from (C) (Surface TLR4: con, n = 10; LPS, n = 10; ALWPs + LPS, n = 10; Total TLR4: con, n = 4; LPS, n = 4; ALWPs + LPS, n = 4). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30319390), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-310202415535173.jpg)
![Immunocytochemistry/ Immunofluorescence: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Pericryptal Myofibroblasts are Responsible for Increased TLR4 Expression in a Subset of CRCs. A) CRCs were separated into two groups representing low- & high- stromal expression of TLR4 by IHC staining. In normal tissue, stromal TLR4 expression is mainly due to macrophages (Green: TLR4, Red: CD68, Merge: TLR4 + CD68 + DAPI (blue)). Conversely, in CRCs increased vimentin & decreased CD68 staining in the pericryptal space confirm that this signal was due to pericryptal myofibroblasts & not related to tumor-associated macrophages. B) Double-stained immunofluorescence for TLR4 (green) & vimentin (red) in normal (I), adenoma (II), & colon adenocarcinoma (III) (10×). In the stromal compartment of CRCs, immunofluorescent staining for TLR4 localized to the pericryptal myofibroblasts in a subset of samples. C) IHC staining of colon adenocarcinoma for TLR4, vimentin, & alpha -SMA (40×). Staining co-localizes to the pericryptal space, confirming the signal arises from pericryptal myofibroblasts. D, E, & F) An increase in IHC staining for alpha -SMA & vimentin was noted in CRCs when compared to normal or low grade dysplasia. A decrease in staining for CD68 positive macrophages was observed with higher degrees of dysplasia. Image collected & cropped by CiteAb from the following publication (//jeccr.biomedcentral.com/articles/10.1186/1756-9966-33-45), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-31020241612688.jpg)
![Western Blot: IL-1 beta/IL-1F2 Antibody [NB600-633] - Methylene blue (M) inhibits NLRP3 inflammasome formation in post-spinal cord injury (SCI) microglia compared to sham (V). Expression of pro-IL-1B and mature IL-1B in microglia sorted from post-SCI spinal cords. Representative Western blot images are shown in (B). Image collected and cropped by CiteAb from the following publication (//journal.frontiersin.org/article/10.3389/fncel.2017.00391/full) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/IL-1-beta-IL-1F2-Antibody-Western-Blot-NB600-633-img0012.jpg "<b>Biological Strategies Validation. </b>Western Blot: IL-1 beta/IL-1F2 Antibody [NB600-633] - Methylene blue (M) inhibits NLRP3 inflammasome formation in post-spinal cord injury (SCI) microglia compared to sham (V). Expression of pro-IL-1B and mature IL-1B in microglia sorted from post-SCI spinal cords. Representative Western blot images are shown in (B). Image collected and cropped by CiteAb from the following publication (//journal.frontiersin.org/article/10.3389/fncel.2017.00391/full) licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: IL-1 beta/IL-1F2 Antibody [NB600-633] - Trabecular Meshwork (TM) region of pig eyes were stained with IL-1 beta antibody (red). Image from verified customer review.](http://images.novusbio.com/fullsize/IL-1-beta-IL-1F2-Antibody-Immunocytochemistry-Immunofluorescence-NB600-633-img0009.jpg)
![Immunohistochemistry: IL-1 beta/IL-1F2 Antibody [NB600-633] - Analysis of: Human IL1beta antibody Secondary antibody: Peroxidase goat anti-rabbit at 1:10,000 for 45 min at RT Localization: cytoplasm Staining: Close up of medullary lymph node: positive staining in the cytoplasm of circulating macrophages. Neg Ctr (far right) normal rabbit IgG with pH 6.2 40X](http://images.novusbio.com/fullsize/IL-1-beta-IL-1F2-Antibody-Immunohistochemistry-NB600-633-img0010.jpg)
![Western Blot: IL-1 beta/IL-1F2 Antibody [NB600-633] - Analysis of IL-1 beta in Rhesus fetal membrane using anti-IL-1 beta antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/IL-1-beta-IL-1F2-Antibody-Western-Blot-NB600-633-img0005.jpg)
![Western Blot: IL-1 beta/IL-1F2 Antibody [NB600-633] - Antibody was used at a 1:200 dilution incubated 1h at room temperature to detect dog IL-1b by Western blot. Lane 1 and 2 were loaded with 2.5 ug and 500 ng of dog IL-1b respectively. The molecular weight of the detected band is estimated by comparison to molecular weight markers (not shown). Detection occurred using a 1:3,000 dilution of IRDye (TM) 800 conjugated Donkey anti-Rabbit IgG for 1h at room temperature.](http://images.novusbio.com/fullsize/IL-1-beta-IL-1F2-Antibody-Western-Blot-NB600-633-img0006.jpg)
![Western Blot: IL-1 beta/IL-1F2 Antibody [NB600-633] - pro-IL-1beta in glioblastoma cells. Image from verified customer review.](http://images.novusbio.com/fullsize/IL-1-beta-IL-1F2-Antibody-Western-Blot-NB600-633-img0008.jpg)
![Western Blot: IL-1 beta/IL-1F2 Antibody [NB600-633] - Lane 1: Human IL-1Beta. Load: 5 ng per lane. Primary antibody: Human IL-1Beta antibody at 1:2,000 for overnight at 4C. Secondary antibody: Peroxidase rabbit secondary antibody at 1:40,000 for 30 min at RT. Block: Blocking Buffer for Fluorescent Western Blotting for 30 min at RT. Predicted/Observed size: 17 kDa, 17 kDa for Human IL-1Beta. Other band(s): Unspecific band at 35 kDa.](http://images.novusbio.com/fullsize/IL-1-beta-IL-1F2-Antibody-Western-Blot-NB600-633-img0011.jpg)
![Western Blot: IL-1 beta/IL-1F2 Antibody [NB600-633] - Methylene blue inhibits inflammasome formation in cultured microglia. (A) Expression of Pro-Caspase-1, Caspase-1 p20, pro-IL-1 beta & mature IL-1 beta in microglia with or without stimulation in the presence or absence of methylene blue. Left: representative Western blot images. Right: statistics. N = 5 per group. The (B) expression of NLRP3, NLRC4 & Aim2 in microglia. Left: representative Western blot images. Right: statistics. N = 4 per group. (C) Co-immunoprecipitation assay showing the binding of ASC to NLRP3 or NLRC4. Left: representative Western blot images. Right: statistics. Un: no stimulation. LPS+ATP: stimulation with LPS followed by ATP treatment. V: vehicle; M: 500 nM methylene blue. IP: immunoprecipitation with the antibody against indicated protein. IB: detection of indicated protein. To analyze the relative expression of target proteins, the band intensities of target proteins were normalized to corresponding band intensities of alpha -Tubulin, followed by calculating the expression in other groups relative to “Un (V)” group. N = 4 per group. *p < 0.05; **p < 0.01; ***p < 0.001 in comparison with unstimulated cells of the vehicle group. #p < 0.05; ##p < 0.01 in comparison with stimulated cells of the vehicle group. Image collected & cropped by CiteAb from the following publication (//journal.frontiersin.org/article/10.3389/fncel.2017.00391/full), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-633_rabbit-polyclonal-il-1-beta-il-1f2-antibody-310202416165633.jpg)
![Western Blot: Rabbit Polyclonal IL-1 beta/IL-1F2 Antibody [NB600-633] - IL-1 beta/IL-1F2 Western blot of liver homogenate from control (1) and alcohol-fed mice (2). Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nb600-633_rabbit-polyclonal-il-1-beta-il-1f2-antibody-western-blot-25112024153834..png)
![Western Blot: ZEB1 Antibody [NBP1-05987] - Samples: Whole cell lysate (15 ug) from HeLa, HEK293T, Jurkat, mouse TCMK-1, and mouse NIH 3T3 cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-ZEB1 antibody (NBP1-05987) used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.](http://images.novusbio.com/fullsize/ZEB1-Antibody-Western-Blot-NBP1-05987-img0017.jpg "Western Blot: ZEB1 Antibody [NBP1-05987] - Samples: Whole cell lysate (15 ug) from HeLa, HEK293T, Jurkat, mouse TCMK-1, and mouse NIH 3T3 cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-ZEB1 antibody (NBP1-05987) used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.")
![Immunohistochemistry-Paraffin: ZEB1 Antibody [NBP1-05987] - Sample: FFPE section of human breast carcinoma. Antibody: Affinity purified rabbit anti-ZEB1 (NBP1-05987) used at a dilution of 1:1000 (0.2 ug/ml). Detection: DAB.](http://images.novusbio.com/fullsize/ZEB1-Antibody-Immunohistochemistry-Paraffin-NBP1-05987-img0019.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - Analysis of ZEB1 in transfected and native mouse cell lysate. Image courtesy of anonymous customer review.](http://images.novusbio.com/fullsize/ZEB1-Antibody-Western-Blot-NBP1-05987-img0003.jpg)
![Immunohistochemistry-Paraffin: ZEB1 Antibody [NBP1-05987] - Analysis of ZEB1 in human liver and spleen tissues. Image courtesy of anonymous customer review.](http://images.novusbio.com/fullsize/ZEB1-Antibody-Immunohistochemistry-Paraffin-NBP1-05987-img0004.jpg)
![Immunohistochemistry-Paraffin: ZEB1 Antibody [NBP1-05987] - Sample: FFPE section of human breast carcinoma. Antibody: Affinity purified rabbit anti-ZEB1 (NBP1-05987) used at a dilution of 1:1000 (0.2 ug/ml). Detection: DAB.](http://images.novusbio.com/fullsize/ZEB1-Antibody-Immunohistochemistry-Paraffin-NBP1-05987-img0018.jpg)
![<b>Independent Antibodies Validation. </b>Immunoprecipitation: ZEB1 Antibody [NBP1-05987] - Detection of human ZEB1 by western blot of immunoprecipitates. Samples: Whole cell lysate (1.0 mg per IP reaction; 20% of IP loaded) from HeLa cells prepared using NETN lysis buffer. Antibodies: Affinity purified rabbit anti-ZEB1 antibody NBP1-05987 used for IP at 3 ug per reaction. ZEB1 was also immunoprecipitated by another rabbit anti-ZEB1 antibody. For blotting immunoprecipitated ZEB1, NBP1-05987 was used at 0.4 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.](http://images.novusbio.com/fullsize/ZEB1-Antibody-Immunoprecipitation-NBP1-05987-img0013.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - Lin28a & ETM-related protein expression changed after the knockdown of Zeb1 in mESCs, mEB, GC1, & P19. Western blotting demonstrated that E-cadherin protein expression increased & that Lin28a & Vimentin protein expression decreased in Zeb1-siRNA transfected mESC (panel a), mEB (panel b), GC1 (panel c), & P19 (panel d) cells. Each experiment was performed in triplicate. Abbreviations: NC, negative control; siRNA, small interfering RNA; & WT, wild-type. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35611144), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-310202415382430.jpg)
![Immunohistochemistry: ZEB1 Antibody [NBP1-05987] - Immunohistochemical staining results of EMT regulators in HG‐PanIN: SNAIL, SLUG, TWIST1, & ZEB1. We categorized & defined three grades: grade 0, <10% positive staining; grade 1, 10%‐50% positive; grade 2, 50%< positive Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30791220), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-310202415291996.jpg)
![Immunocytochemistry/ Immunofluorescence: ZEB1 Antibody [NBP1-05987] - Location of Zeb1 proteins in mEC lines (mESC, mEB, GC1, & P19). Immunofluorescence analysis was used to determine localization of Zeb1 in mESC, mEB, GC1, & P19 using a Zeb1 antibody (red). Cell nuclei were labeled with Hoechst 33342 (blue). The scale for the measurement bar is 50 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35611144), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-31020241539712.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - Lin28a & ETM-related protein expression changed after the knockdown of Zeb1 in mESCs, mEB, GC1, & P19. Western blotting demonstrated that E-cadherin protein expression increased & that Lin28a & Vimentin protein expression decreased in Zeb1-siRNA transfected mESC (panel a), mEB (panel b), GC1 (panel c), & P19 (panel d) cells. Each experiment was performed in triplicate. Abbreviations: NC, negative control; siRNA, small interfering RNA; & WT, wild-type. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35611144), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-31020241529198.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - Lin28a & ETM-related protein expression changed after the knockdown of Zeb1 in mESCs, mEB, GC1, & P19. Western blotting demonstrated that E-cadherin protein expression increased & that Lin28a & Vimentin protein expression decreased in Zeb1-siRNA transfected mESC (panel a), mEB (panel b), GC1 (panel c), & P19 (panel d) cells. Each experiment was performed in triplicate. Abbreviations: NC, negative control; siRNA, small interfering RNA; & WT, wild-type. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35611144), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-310202415304286.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - Zeb1 expression in mESCs, mEB, GC1, & P19. (a) Zeb1 mRNA expression detected by real-time qPCR in mESC, mEB, GC1, & P19 (P < 0.001, data presented as mean value ± SD). (b) Zeb1 protein expression examined by western blot in mESC, mEB, GC1, & P19. Each experiment was performed in triplicate. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35611144), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-310202415304288.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - Lin28a & ETM-related protein expression changed after the knockdown of Zeb1 in mESCs, mEB, GC1, & P19. Western blotting demonstrated that E-cadherin protein expression increased & that Lin28a & Vimentin protein expression decreased in Zeb1-siRNA transfected mESC (panel a), mEB (panel b), GC1 (panel c), & P19 (panel d) cells. Each experiment was performed in triplicate. Abbreviations: NC, negative control; siRNA, small interfering RNA; & WT, wild-type. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35611144), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-31020241528450.jpg)
![Immunocytochemistry/ Immunofluorescence: ZEB1 Antibody [NBP1-05987] - Correlation of the expression of ZEB1 & IL‐6 & other cytokines in various cancers. (A) Correlation analysis of the expression of ZEB1 & cytokines in breast cancer cell lines using data obtained from the Cancer Cell Line Encyclopedia (CCLE). Breast cancer cell lines were selected for the analysis, & each dot represents a cell line. Affymetrix microarray probe IDs for IL6 & IL8 are shown after the gene symbols on the y‐axis. RMA, robust multiarray average. (B) Representative results obtained from the tissue array analysis in Fig. S3. The top panel shows a case that was positive for both nuclear ZEB1 staining (green) & whole‐cell IL‐6 staining (red); scores = 4. The bottom panel shows a case that was negative for both ZEB1 & IL‐6; scores = 1. The samples were counterstained with DAPI to show cell density in the spot. Original magnification: 20 ×. (C) Kaplan–Meier survival curves of breast & lung cancer patients obtained from a public meta‐analysis database & Kaplan–Meier plotter (Gyorffy et al., 2010, 2013). The probability of overall survival of patients as split by median IL6 & IL8 expression is shown. Red: IL6 & IL8 high expression group; black: IL6 & IL8 low expression group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28618162), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-31020241616091.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - SU5402, FGFR1 inhibitor, affects the EMT transcription factors.(A, B) ERK1/2 phosphorylation (p-ERK1/2) determined by immunoblotting in HSC-4 & OTC-04 treated for 30 min w/ 30 ng/ml FGF2 or 30 ng/ml FGF7 in presence of 10% FBS (A) & in TSU & HOC313 cells treated for 1 h w/ 30 ng/ml FGF2 or 30 μM SU5402 in absence of FBS (B). F2, FGF2; F7, FGF7; SU, SU5402. (C) We have previously reported that, after treatment w/ TGF-beta , NMuMG cells underwent EMT w/ the IIIc-isoform of FGFR1[17]. After NMuMG cells pretreated w/ TGF-beta transfected w/ mouse Fgfr1 siRNA or treated w/ SU5402, the cells further incubated in culture medium (CM) from TSU cells. SU, SU5402; siFR1, siRNA against mouse Fgfr1. (D)FGF2 mRNA levels determined by RT-qPCR analyses. The ratio of FGF2 mRNA to GAPDH mRNA in HSC-4 cells indicated as “1”. Each value represents the mean ± SD of triplicate determinations from a representative experiment. Similar results obtained in at least three independent experiments. (E) ERK1/2 phosphorylation (p-ERK1/2) in TSU & HOC313 cells monitored in presence of indicated concentration of SU5402 for 1 h under serum-free culture conditions, followed by immunoblot analysis. (F, G) Expression of indicated genes in TSU cells under serum-free culture conditions determined by RT-qPCR (F) & immunoblot (G) analyses, following treatment w/ 10 μM SU5402. Each value represents the mean ± SD of triplicate determinations from a representative experiment. Similar results obtained from at least three independent experiments. p values determined by Student’s t-test. **p < 0.01. (H) TSU cells treated w/ 10 μM U0126 in absence of FBS subjected to immunoblotting w/ the indicated antibodies. alpha -tubulin used as a loading control (A, B, C, E, G, & H). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31682640), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-31020241616017.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - SU5402, FGFR1 inhibitor, affects the EMT transcription factors.(A, B) ERK1/2 phosphorylation (p-ERK1/2) determined by immunoblotting in HSC-4 & OTC-04 treated for 30 min w/ 30 ng/ml FGF2 or 30 ng/ml FGF7 in presence of 10% FBS (A) & in TSU & HOC313 cells treated for 1 h w/ 30 ng/ml FGF2 or 30 μM SU5402 in absence of FBS (B). F2, FGF2; F7, FGF7; SU, SU5402. (C) We have previously reported that, after treatment w/ TGF-beta , NMuMG cells underwent EMT w/ the IIIc-isoform of FGFR1[17]. After NMuMG cells pretreated w/ TGF-beta transfected w/ mouse Fgfr1 siRNA or treated w/ SU5402, the cells further incubated in culture medium (CM) from TSU cells. SU, SU5402; siFR1, siRNA against mouse Fgfr1. (D)FGF2 mRNA levels determined by RT-qPCR analyses. The ratio of FGF2 mRNA to GAPDH mRNA in HSC-4 cells indicated as “1”. Each value represents the mean ± SD of triplicate determinations from a representative experiment. Similar results obtained in at least three independent experiments. (E) ERK1/2 phosphorylation (p-ERK1/2) in TSU & HOC313 cells monitored in presence of indicated concentration of SU5402 for 1 h under serum-free culture conditions, followed by immunoblot analysis. (F, G) Expression of indicated genes in TSU cells under serum-free culture conditions determined by RT-qPCR (F) & immunoblot (G) analyses, following treatment w/ 10 μM SU5402. Each value represents the mean ± SD of triplicate determinations from a representative experiment. Similar results obtained from at least three independent experiments. p values determined by Student’s t-test. **p < 0.01. (H) TSU cells treated w/ 10 μM U0126 in absence of FBS subjected to immunoblotting w/ the indicated antibodies. alpha -tubulin used as a loading control (A, B, C, E, G, & H). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31682640), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-31020241616067.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - Vimentin & ZEB1 protein levels are regulated by OVOL1 & OVOL2 in a human SCC cell line. (A) Relative protein expression levels of OVOL1 & OVOL2 in A431 cells treated with control siRNA, OVOL1 siRNA, or OVOL2 siRNA for 48 h. (Left) Representative blot images & (right) relative expression levels calculated from three independent experiments. (B) Relative protein expression levels of vimentin, ZEB1, & E-cadherin in A431 cells treated with control siRNA, OVOL1 siRNA, or OVOL2 siRNA for 72 h. (Upper) representative blot images & (lower) relative protein expression levels calculated from three independent experiments. Mann–Whitney U-test; error bars represent mean ± standard deviation. Protein expressions are relative to those of beta -actin as a reference. The control siRNA value was set to 1. p-values < 0.05 were assumed to indicate a statistically significant difference; * p < 0.05. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32106476), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-310202416175281.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - PDGFR-alpha / beta promotes sarcoma CSC migration/invasion & anchorage-independent growth.a Western blot analysis of cell adhesion protein N-cadherin & EMT transcription factors Snail, Slug, & Zeb1 in human sarcoma cell lines grown as monolayers & as spheroids. beta -actin was used as the loading control. b Representative images under light microscopy of migration & invasion assays of human sarcoma cell lines grown as monolayers or as spheroids for 24–48 h. Graphs display the number of migrated or invasive cells per field. c Representative light microscopy images of forrmed colonies in soft agar assay of human sarcoma cell lines grown as monolayers or spheroids for 14–20 days. Graph displays the number colonies per field. d Representative images under light microscopy of migration & invasion assays of human sarcoma cell lines grown as monolayers or as spheroids. Spheroid cells were treated with imatinib or DMSO. e Western blot analysis of N-cadherin & EMT-regulating transcription factors in human sarcoma cell lines grown as spheroids & treated with imatinib or DMSO. Experiments in a & e were performed three times with similar results. Bars represent standard deviation. *p < 0.05 compared to Monolayers Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/s41389-018-0059-1), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-310202416182642.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - FGFR1 siRNAs attenuate the malignant phenotypes of cancer cells.(A) mRNA from TSU cells transfected with siRNAs against FGFR1 (siFGFR1) were subjected to conventional RT-PCR to determine the levels of endogenous FGFR1. (B, C, D) After transfection with siFGFR1 in TSU cells, phosphorylation of ERK1/2 (p-ERK1/2) (B), ZEB1 levels (C), & cell morphology (D) were determined. (E) TSU cells transfected with siFGFR1 were subjected to immunofluorescence analyses. Low magnification, 40×; high magnification, 80×. (F, G, H, I) After either treatment with SU5402 or transfection with siFGFR1 in TSU & HOC313 cells, the number of cells & invasive properties were determined under serum-free culture conditions. (J & K) After transfection with siFGFR1c in TSU & HOC313 cells, invasive & migratory properties were determined under serum-free culture conditions in TSU & HOC313 cells, respectively. siNC, non-specific control siRNA. Each value represents the mean ± SD of triplicate determinations from a representative experiment. Similar results were obtained from at least three independent experiments. p values were determined by Student’s t-test. *p < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31682640), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-310202416175241.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - PDGFR-alpha / beta promotes sarcoma CSC migration/invasion & anchorage-independent growth.a Western blot analysis of cell adhesion protein N-cadherin & EMT transcription factors Snail, Slug, & Zeb1 in human sarcoma cell lines grown as monolayers & as spheroids. beta -actin was used as the loading control. b Representative images under light microscopy of migration & invasion assays of human sarcoma cell lines grown as monolayers or as spheroids for 24–48 h. Graphs display the number of migrated or invasive cells per field. c Representative light microscopy images of forrmed colonies in soft agar assay of human sarcoma cell lines grown as monolayers or spheroids for 14–20 days. Graph displays the number colonies per field. d Representative images under light microscopy of migration & invasion assays of human sarcoma cell lines grown as monolayers or as spheroids. Spheroid cells were treated with imatinib or DMSO. e Western blot analysis of N-cadherin & EMT-regulating transcription factors in human sarcoma cell lines grown as spheroids & treated with imatinib or DMSO. Experiments in a & e were performed three times with similar results. Bars represent standard deviation. *p < 0.05 compared to Monolayers Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/s41389-018-0059-1), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-310202416163718.jpg)
![Western Blot: ZEB1 Antibody [NBP1-05987] - Nav1.4 protein levels are decreased in muscles from mouse models of SMA. (A) Immunoblot analysis using muscle lysate from P2, P5, P9, & P21 wild type mice. Nav1.4 protein levels increase during postnatal muscle development & form the predominant sodium channel expressed in mature skeletal muscle. GAPDH served as a loading control (N = 3). (B) Representative immunoblot with quantification, showing a decrease in levels of sodium channel Nav1.4 & Nav1.5 in P5 Smn-/-;SMN2 hindlimb muscle compared with controls (N = 3). (C) Quantification of immunoblot analyses in P21 Smn2B/- & control hindlimb muscles revealed a decrease in Nav1.4 levels. Early in postnatal muscle development, the Nav1.5 sodium channel isoform is the most predominant. In P21 Smn2B/- mice, the protein levels of Nav1.5 are higher than in controls (N = 3). (D) The protein level of the Nav1.4 positive regulator, NF1, is not altered in muscles from P21 Smn2B/- mice. Similarly, no change was detected in the protein levels of the Nav1.4 repressor ZEB. (E) Expression of sodium channel Nav1.4 in control sham & denervated samples 1 & 7 days post-denervation was assessed by immunoblot (N = 3). A decrease in the levels of Nav1.4 in muscle was noted at 7 days post-denervation. *, P < 0.05; **, P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24119341), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-05987_rabbit-polyclonal-zeb1-antibody-31020241617522.jpg)
![Flow Cytometry: TLR2 Antibody (TL2.1) [NB100-56722] - Analysis using the FITC conjugate of NB100-56726. Surface staining of stable HEK293/hTLR2 cells (IML-202, red) and vector control cells (IML-200, green) using TLR2 antibody at 1 ug/10^6 cells.](http://images.novusbio.com/fullsize/TLR2-Antibody-TL2-1-Flow-Cytometry-NB100-56722-img0005.jpg "Flow Cytometry: TLR2 Antibody (TL2.1) [NB100-56722] - Analysis using the FITC conjugate of NB100-56726. Surface staining of stable HEK293/hTLR2 cells (IML-202, red) and vector control cells (IML-200, green) using TLR2 antibody at 1 ug/10^6 cells.")
![Western Blot: TLR2 Antibody (TL2.1) [NB100-56722] - Expression of TLR2 was determined by western blotting. The immunoreactivity of the anti-TLR2 was confirmed with human intestinal lysate. Data are representative for analysis of >=2 independent experiments. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0060671) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR2-Antibody-TL2-1-Western-Blot-NB100-56722-img0015.jpg)
![Western Blot: TLR2 Antibody (TL2.1) [NB100-56722] - Total protein from human THP-1 and U937 cells was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-TLR2 (NB100-56722) in 5% BSA-TBST and detected with an anti-mouse HRP secondary antibody using NovaLume chemiluminescence detection reagent (NPB2-61915).](http://images.novusbio.com/fullsize/TLR2-Antibody-TL2-1-Western-Blot-NB100-56722-img0016.jpg)
![Flow Cytometry: TLR2 Antibody (TL2.1) [NB100-56722] - Monitoring of TLR2 expression in normal B cells and primary MCL cells cultured for 24h in the absence/presence of CD40L, IL-4, and TLR ligands. Filled curves refer to isotypic control, empty curves to the TLR2 antibody (NB100-56722) of untreated samples. Dotted histograms represent CD40L+IL4 activated cells, dashed curves indicate CD40L+IL4 activated cells further treated with TLR ligands. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0153823) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR2-Antibody-TL2-1-Flow-Cytometry-NB100-56722-img0013.jpg)
![Flow (Cell Surface): TLR2 Antibody (TL2.1) [NB100-56722] - Flow (Cell Surface): - Azide Free [NB100-56726] - Analysis using the PE conjugate of NB100-56726. Staining of TLR2 on stable transfected cell line using this antibody at 1 ug/10^6 cells. Green: isotype control. Red: anti-TLR2 antibody. Image using the Azide Free form of this antibody.](http://images.novusbio.com/fullsize/TLR2-Antibody-TL2-1-Flow-Cell-Surface-NB100-56722-img0010.jpg)
![Block/Neutralize: TLR2 Antibody (TL2.1) [NB100-56722] - Human monocyte-derived DCs were pre-incubated wit TLR-neutralizing antibodies including TLR2 antibody (NB100-56722) for 1 h. Afterwards, DCs were infected with H. pylori G27 (MOI 5) and the levels of the costimulatory molecule CD86 and the maturation marker CD83 were analyzed by FACS on CD11c+ cells 24 h post-infection. Data are presented as mean +/- SD of five independent experiments. *p<=0.05, **p<=0.005, ***p<=0.0005. Asterisks on top of bars indicate significance relative to non-neutralized, H. pylori-primed control cells. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0104804) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR2-Antibody-TL2-1-Block-Neutralize-NB100-56722-img0014.jpg)
![Flow Cytometry: TLR2 Antibody (TL2.1) - BSA Free [NB100-56722] - Intracellular flow analysis of TLR2 in 1x10^6 PBMCs using 2 ug of NB100-56722. Shaded histogram represents cells without antibody; green represents isotype control; purple represents anti-TLR2 antibody.](http://images.novusbio.com/fullsize/nb100-56722_mouse-monoclonal-tlr2-antibody-tl2-1-17720241003212.jpg)
![Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - An intracellular stain was performed on Raji cells with Adiponectin antibody NB100-65810 (blue) and a matched isotype control NBP2-24893 (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by Dylight488-conjugated anti-rabbit secondary antibody. Image using the Azide Free form of this antibody.](http://images.novusbio.com/fullsize/Rabbit--Mouse-IgG-Isotype-Control-Flow-Cytometry-NBP2-24891-img0006.jpg)
![Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.](http://images.novusbio.com/fullsize/Rabbit--Mouse-IgG-Isotype-Control-Flow-Cytometry-NBP2-24891-img0001.jpg)
![Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - PBMCs fixed and permeabilized using the Novus intracellular staining kit and stained with 1 ug of TLR7-PE conjugate (red) or rabbit IgG-PE conjugate isotype control (NBP2-24983, green). Image using the PE form of this antibody.](http://images.novusbio.com/fullsize/Rabbit--Mouse-IgG-Isotype-Control-Flow-Cytometry-NBP2-24891-img0002.jpg)
![Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular analysis of TLR1 in human PBMCs (lymphocyte-gated) using this antibody. Shaded histogram represents cells alone, green represents isotype control , red represents TLR1 antibody. TLR intracellular flow kit was used for this test. Image using the Alexa Fluor 488 form of this antibody.](http://images.novusbio.com/fullsize/Rabbit--Mouse-IgG-Isotype-Control-Flow-Cytometry-NBP2-24891-img0003.jpg)
![Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Analysis of TLR7 in Ramos cells using 2 ug of NBP2-24892. Shaded histogram represents FITC-conjugated rabbit IgG isotype control ; red represents anti-TLR7 antibody. Image using the FITC form of this antibody.](http://images.novusbio.com/fullsize/Rabbit--Mouse-IgG-Isotype-Control-Flow-Cytometry-NBP2-24891-img0004.jpg)
![Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - FLOW analysis of Mouse CD4+ T cells that were stimulated with anti-CD3/CD28 beads and insulin (1ug/mL) for 5 days in culture media with additional glucose provided. PE conjugated Glut1 antibody stained cells (NB110-39113PE, Orange) were included as positive control which were compared with Rb IgG PE, NBP2-24983 as Isotype Control (Blue) as well as with fluorescence minus one/FMO control (Red) [Image submitted by Verified Customer - see Review for Protocol Details]. Image using the PE form of this antibody.](http://images.novusbio.com/fullsize/Rabbit--Mouse-IgG-Isotype-Control-Flow-Cytometry-NBP2-24891-img0005.jpg)
![Immunocytochemistry/ Immunofluorescence: Rabbit IgG Isotype Control [NBP2-24891] - The expression & localization of PRCP in the human atherosclerotic plaque. (A) Immunohistochemical staining of PRCP (brown color) in a carotid endarterectomy sample. Scale bars, 500 µm (left) & 50 µm (right). (B) A consecutive section of the carotid sample was immunofluorescently stained for PRCP (red) & Mac-2 (green), & counterstained with DAPI. Cells that clearly express both PRCP & Mac-2 are indicated by white arrows. Scale bars, 500 µm (left) & 50 µm (right). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30305673), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-24891_rabbit-igg-isotype-control-31020241539599.jpg)
![Immunohistochemistry: Rabbit IgG Isotype Control [NBP2-24891] - alpha -melanocyte stimulating hormone ( alpha -MSH) is expressed by plaque macrophages in human atheroma. (A) alpha -MSH immunostaining (brown color) of carotid endarterectomy sample. Scale bars, 200 µm (left) & 50 µm (right). (B) A consecutive section of the carotid sample was immunofluorescently stained for alpha -MSH (red) & Mac-2 (green), & counterstained with DAPI. Cells that clearly express both alpha -MSH & Mac-2 are indicated by white arrows. Scale bars, 200 µm (left) & 50 µm (right). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30305673), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-24891_rabbit-igg-isotype-control-310202415392523.jpg)
![Immunohistochemistry-Paraffin: TLR5 Antibody (19D759.2) [NBP2-24787] - Analysis of FFPE tissue section of normal human skin using 5 ug/ml concentration of TLR5 antibody (clone 19D759.2). Intense membrane staining of TLR5 was observed specifically in the pigmented basel cells of epidermal layer [10X Magnification]](http://images.novusbio.com/fullsize/TLR5-Antibody-19D759-2-Immunohistochemistry-Paraffin-NBP2-24787-img0005.jpg "Immunohistochemistry-Paraffin: TLR5 Antibody (19D759.2) [NBP2-24787] - Analysis of FFPE tissue section of normal human skin using 5 ug/ml concentration of TLR5 antibody (clone 19D759.2). Intense membrane staining of TLR5 was observed specifically in the pigmented basel cells of epidermal layer [10X Magnification]")
![<b>Biological Strategies Validation. </b>Flow Cytometry: TLR5 Antibody (19D759.2) [NBP2-24787] - Analysis using the PE conjugate of NBP2-24787. Staining of CD14-/CD83+/TLR5+ diffferentiated myeloid dendritic cells (mDCs). PBMCs were stimulated 5 days with GM-CSF+IL4 prior to the staining. The cells were stained for surface markers CD14 and CD83 FITC, and TLR5 PE. CD14- cells were gated and stained with PE-conjugated isotype control (mouse IgG2a), and FITC-conjugated CD83 (left). CD14- cells were gated and stained with 1 ug PE-conjugated TLR5 , and FITC-conjugated CD83 (right).](http://images.novusbio.com/fullsize/TLR5-Antibody-19D759-2-Flow-Cytometry-NBP2-24787-img0011.jpg)
![Western Blot: TLR5 Antibody (19D759.2) [NBP2-24787] - BEAS-2B cells whole cell lysate. Image from verified customer review.](http://images.novusbio.com/fullsize/TLR5-Antibody-19D759-2-Western-Blot-NBP2-24787-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: TLR5 Antibody (19D759.2) [NBP2-24787] - Staining using in-vitro cultured fixed non-permeabilized MCF7 breast cancer cells (ATCC). EpCAM (cell membrane) staining is represented in green (FITC filter), nuclei staining is represented in blue (DAPI filter). Image from a verified customer review using the Alexa Fluor 488 conjugated format of this antibody.](http://images.novusbio.com/fullsize/TLR5-Antibody-19D759-2-Immunocytochemistry-Immunofluorescence-NBP2-24787-img0012.jpg)
![Immunohistochemistry: TLR5 Antibody (19D759.2) [NBP2-24787] - TLR5 and TLR7 expression in nasopharyngeal carcinoma and in the normal epithelium. Mild positive TLR5 expression in NK-U. Strong positive TLR5 expression in KSCC. Image collected and cropped by CiteAb from the following publication (//bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5816-9), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR5-Antibody-19D759-2-Immunohistochemistry-NBP2-24787-img0013.jpg)
![Flow Cytometry: TLR5 Antibody (19D759.2) - BSA Free [NBP2-24787] - Flow analysis of TLR5 in mouse MC38 cells. Image from verified customer review.](http://images.novusbio.com/fullsize/TLR5-Antibody-19D759-2-BSA-Free-Flow-Cytometry-NBP2-24787-img0014.jpg)
![Immunohistochemistry-Paraffin: TLR5 Antibody (19D759.2) [NBP2-24787] - Human skin stained with TLR5 antibody (5 ug/ml), peroxidase-conjugate and DAB chromogen.](http://images.novusbio.com/fullsize/TLR5-Antibody-19D759-2-Immunohistochemistry-Paraffin-NBP2-24787-img0004.jpg)
![Immunohistochemistry-Paraffin: TLR5 Antibody (19D759.2) [NBP2-24787] - Analysis of TLR5 in FFPE mouse brain tissue using TLR5 antibody at 5 ug/ml.](http://images.novusbio.com/fullsize/TLR5-Antibody-19D759-2-Immunohistochemistry-Paraffin-NBP2-24787-img0002.jpg)
![Flow Cytometry: TLR5 Antibody (19D759.2) [NBP2-24787] - Intracellular flow analysis of TLR5 in human monocytes using 0.5 ug of TLR5 antibody. Shaded histogram represents cells without antibody; green represents isotype control; red represents TLR5 antibody. this antibody secondary antibody was used in this test.](http://images.novusbio.com/fullsize/TLR5-Antibody-19D759-2-Flow-Cytometry-NBP2-24787-img0003.jpg)
![Immunohistochemistry-Paraffin: CD3 Antibody (SP7) [NB600-1441] - FFPE human tonsil stained with CD3 antibody.](http://images.novusbio.com/fullsize/CD3-Antibody-SP7-Immunohistochemistry-Paraffin-NB600-1441-img0001.jpg "Immunohistochemistry-Paraffin: CD3 Antibody (SP7) [NB600-1441] - FFPE human tonsil stained with CD3 antibody.")
![Immunohistochemistry-Frozen: CD3 Antibody (SP7) [NB600-1441] - T-cells and microglia in mouse spinal cord with acute EAE. Mouse was perfused with 4% paraformaldehyde. Spinal cord was post-fixed overnight, followed by cryoprotection with 30% sucrose for 24h. Spinal cord sections were treated with antigen-retrieval buffer (pH 6.0) at 60C for 10 min, then cooled down to room temperature (this step should not be omitted). Anti-CD3 antibody was diluted at 1:200. Incubation: room temperature overnight. IHC-Fr image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD3-Antibody-SP7-Immunohistochemistry-Frozen-NB600-1441-img0002.jpg)
![<b>Genetic Strategies Validation. </b>Immunohistochemistry-Paraffin: CD3 Antibody (SP7) [NB600-1441] - Mouse lung tissue stained against C3aR normal conditions (left) and knockdown conditions (right). IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD3-Antibody-SP7-Immunohistochemistry-Paraffin-NB600-1441-img0003.jpg)
![TLR4 Inhibitor Peptide Set [NBP2-26244] - The inhibitor peptide inhibits TLR4 signaling by blocking interactions between TLR4 and its adaptors Mal/TIRAP and TRAM.](http://images.novusbio.com/fullsize/TLR4-Inhibitor-Peptide-Set-NBP2-26244-img0013.jpg "TLR4 Inhibitor Peptide Set [NBP2-26244] - The inhibitor peptide inhibits TLR4 signaling by blocking interactions between TLR4 and its adaptors Mal/TIRAP and TRAM.")
![Blocking/Neutralizing: TLR4 Inhibitor Peptide Set [NBP2-26244] - iBMDM cultures were pretreated with 5uM of inhibitor or control prior to stimulation with 20 ng/ml LPS. Negative (LPS-, LPS-/CP7+, LPS-/CP7+) and positive (LPS+) controls were also included. Supernatants were harvested after 6 h and murine TNF-alpha measured by ELISA. TLR4 inhibitor, but not the control, inhibited LPS-induced TNF-alpha production. Image courtesy of Dr. Julianne Stack and Dr. Andrew Bowie, Trinity College, Dublin, Ireland.](http://images.novusbio.com/fullsize/TLR4-Inhibitor-Peptide-Set-Blocking-Neutralizing-NBP2-26244-img0015.jpg)
![TLR4 Inhibitor Peptide Set [NBP2-26244] - TLR4/MD-2/CD14/NF-kB/SEAPorter stably transfected cells were plated in 96-well plates at 1x10^5 cells/well. After 16 h, cells were preincubated with various concentrations of inhibitor or control peptides (CP) for 1 h. Cells were then stimulated with 10 ng/ml LPS for 24 h. The secreted alkaline phosphatase (SEAP) was analyzed using the SEAPorter Assay Kit. Inhibitory effect on the LPS-mediated TLR4 activation by the VIPER peptide is shown in panel A, and IC50 of the VIPER peptide is described in panel B.](http://images.novusbio.com/fullsize/TLR4-Inhibitor-Peptide-Set-Blocking-Neutralizing-NBP2-26244-img0016.jpg)
![Immunohistochemistry-Frozen: Rabbit IgG Isotype Control [NB810-56910] - Mouse ear skin (aceton-fixed frozen section) stained with rabbit IgG isotype control, which was used as a negative control. Image from verified customer review.](http://images.novusbio.com/fullsize/Rabbit-IgG-Isotype-Control-Immunohistochemistry-Frozen-NB810-56910-img0012.jpg "Immunohistochemistry-Frozen: Rabbit IgG Isotype Control [NB810-56910] - Mouse ear skin (aceton-fixed frozen section) stained with rabbit IgG isotype control, which was used as a negative control. Image from verified customer review.")
![Immunohistochemistry-Frozen: Rabbit IgG Isotype Control [NB810-56910] - Mouse ear skin (aceton-fixed frozen section) stained with rabbit IgG isotype control, which was used as a negative control. Image from verified customer review.](http://images.novusbio.com/fullsize/Rabbit-IgG-Isotype-Control-Immunohistochemistry-Frozen-NB810-56910-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: CD34 Antibody (MEC 14.7) [NB600-1071] - CD34 antibody was tested in WEHI-3 cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunocytochemistry-Immunofluorescence-NB600-1071-img0003.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of a FFPE tissue section of mouse small intestine using rat anti-mouse CD34 (clone MEC 14.7) at 1:100 dilution. The signal was developed using HRP-conjugated anti-rat secondary with DAB reagent which followed counterstaining of nuclei using hematoxylin. This antibody specifically labelled the endothelial cells in blood vessels located primarily in the sub-mucosa, and of that of the mucosa muscularis and the mucosal lacteal.](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0014.jpg)
![Flow Cytometry: CD34 Antibody (MEC 14.7) [NB600-1071] - CD34 (MEC 14.7) antibody was tested at 1:250 in WEHI-3 cells with DyLight 488 (green) alongside a matched isotype control (black).](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Flow-Cytometry-NB600-1071-img0002.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of CD34 on human renal cancer xenograft using CD34 antibody (clone MEC 14.7). The antibody detected the endothelial cells in the tumor vasculature which are originating from the host (mouse).](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0005.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of a human renal cancer tissue section using CD34 antibody (clone MEC 14.7) at 1:100 dilution. The antibody did not detect human CD34 which is an expected outcome for this clone. This section was included in NB600-1071's IHC validation testing as a negative control.](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0006.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of a FFPE tissue section of human renal cancer xenograft using CD34 antibody clone MEC 14.7 at 1:100 dilution. The signal was developed using HRP-conjugated secondary antibody and DAB reagent followed by counterstaining of nuclei with hematoxylin. Notably, the antibody specifically stained the endothelial cells of the tumor vasculature which is originating from the host animal cells (mouse). This observation was verified by including a negative control in this validation testing (see the IHC image of human renal cancer tissue section with negative signal for CD34).](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0009.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of a FFPE tissue section of human renal cancer xenograft using CD34 antibody (clone MEC 14.7) at 1:100 dilution. The staining was detected using HRP-conjugated secondary antibody and DAB reagent followed by counterstaining of nuclei with hematoxylin. Note that this murine CD34 specific antibody stained only the endothelial cells of the tumor vasculature which is originating from the host animal cells (mouse). This observation was verified by including a negative control in this validation testing (see the IHC image of human renal cancer tissue section with negative signal for CD34).](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0010.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of a FFPE tissue section of mouse colon using rat anti-mouse CD34 (clone MEC 14.7) at 1:100 dilution. The signal was developed using HRP-conjugated anti-rat secondary with DAB reagent which followed counterstaining of nuclei using hematoxylin. The antibody specifically generated a staining of the endothelial cells in blood vessels of the colon.](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0012.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of a FFPE tissue section of mouse heart using rat anti-mouse CD34 (clone MEC 14.7) at 1:100 dilution. The signal was developed using HRP-conjugated anti-rat secondary with DAB reagent which followed counterstaining of nuclei using hematoxylin. The antibody specifically generated a staining of the endothelial cells in blood vessels of the heart tissue.](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0013.jpg)
![Flow Cytometry: CD34 Antibody (MEC 14.7) [NB600-1071] - An intracellular stain was performed on Raw264.7 cells with CD34 Antibody [MEC 14.7] NB600-1071 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rat IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 488 (SA5-10018, Thermo Fisher).](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Flow-Cytometry-NB600-1071-img0015.jpg)
![Immunocytochemistry/Immunofluorescence: CXCR4 Antibody [NB100-74396] - Optimization of immunofluorescence staining of CXCR4 protein. MDA, PC3, KG1 cells were used for the optimization experiments. Cells were seeded onto cell-tak coated 48 mm coverslips in a 48-well plate. Cells were fixed with 2% formaldehyde for 20 min, washed with PBS. After fixation, cells were blocked with 2.0% BSA in PBS for 1 h at room temperature. All the cells were incubated with a primary antibody for anti-rabbit CXCR4 for 1 h. After washing with PBS, cells were put in respective secondary antibodies-anti-rabbit dylight 405 for 1 h. PSMA= Magenta, EpCAM= Yellow, sLex= Green, CXCR4= Red, and Merge shows all the colors. MDA=PSMA+, EpCAM+, sLex+, CXCR4+. PC3 = PSMA-, EpCAM+, sLex-, CXCR4+. KG1 = PSMA-, EpCAM-, sLex+, CXCR4-. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0085143) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CXCR4-Antibody-Immunocytochemistry-Immunofluorescence-NB100-74396-img0008.jpg "Immunocytochemistry/Immunofluorescence: CXCR4 Antibody [NB100-74396] - Optimization of immunofluorescence staining of CXCR4 protein. MDA, PC3, KG1 cells were used for the optimization experiments. Cells were seeded onto cell-tak coated 48 mm coverslips in a 48-well plate. Cells were fixed with 2% formaldehyde for 20 min, washed with PBS. After fixation, cells were blocked with 2.0% BSA in PBS for 1 h at room temperature. All the cells were incubated with a primary antibody for anti-rabbit CXCR4 for 1 h. After washing with PBS, cells were put in respective secondary antibodies-anti-rabbit dylight 405 for 1 h. PSMA= Magenta, EpCAM= Yellow, sLex= Green, CXCR4= Red, and Merge shows all the colors. MDA=PSMA+, EpCAM+, sLex+, CXCR4+. PC3 = PSMA-, EpCAM+, sLex-, CXCR4+. KG1 = PSMA-, EpCAM-, sLex+, CXCR4-. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0085143) licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Western Blot: CXCR4 Antibody [NB100-74396] - The A2AR and baicalin attenuated CXCR4 expression in the hypoxia-induced PAH mouse model. CXCR4 protein expression levels in lung tissue were examined by western blot. GAPDH served as an internal control (c, d; n = 3). Image collected and cropped by CiteAb from the following publication (//www.ncbi.nlm.nih.gov/pmc/articles/PMC5543745/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CXCR4-Antibody-Western-Blot-NB100-74396-img0012.jpg)
![<b>Biological Strategies Validation. </b>Immunohistochemistry: CXCR4 Antibody [NB100-74396] - Pep R54 in combination with nivolumab reduced the expression of CXCR4-CXCL12 and PD-L1 in PES43 tumors. Representative IHC pictures (magnification 400x) for CXCR4, CXCR7 (red staining), CXCL12, PD-1 and PD-L1 expression (brown staining) in PES43 collected tumors from mice treated with Pep R54, nivolumab or combined treatment. Image collected and cropped by CiteAb from the following publication (//jeccr.biomedcentral.com/articles/10.1186/s13046-019-1420-8) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CXCR4-Antibody-Immunohistochemistry-NB100-74396-img0010.jpg)
![<b>Biological Strategies Validation. </b>Immunohistochemistry: CXCR4 Antibody [NB100-74396] - Pep R in combination with anti-PD-1 reduced the expression of CXCR4-CXCL12 and PD-L1 in MC38 tumors. Representative IHC pictures for CXCR4, CXCR7, CXCL12, PD-1 and PD-L1 expression (brown staining) in MC38 collected tumors (magnification 400x), from mice treated with Pep R, anti-murine PD-1 or combined treatment showing the reduction of CXCR4, CXCL12 and PD-L1 expression in mice treated with Pep R alone and in combination with anti-PD-1Image collected and cropped by CiteAb from the following publication (//jeccr.biomedcentral.com/articles/10.1186/s13046-019-1420-8) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CXCR4-Antibody-Immunohistochemistry-NB100-74396-img0011.jpg)
![Western Blot: CXCR4 Antibody [NB100-74396] - Analysis of CXCR4 in HeLa whole cell extract.](http://images.novusbio.com/fullsize/CXCR4-Antibody-Western-Blot-NB100-74396-img0002.jpg)
![Western Blot: CXCR4 Antibody [NB100-74396] - Analysis of CXCR4 protein in human small intestine tissue lysate using 1:500 dilution of rabbit polyclonal CXCR4 antibody (Lot A2). The signal was developed using ECL method and the antibody generated a specific band of CXCR4 at ~40 kDa position.](http://images.novusbio.com/fullsize/CXCR4-Antibody-Western-Blot-NB100-74396-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: CXCR4 Antibody [NB100-74396] - CXCR4 antibody was tested in HeLa cells with FITC (green). Nuclei were counterstained with DAPI (blue).](http://images.novusbio.com/fullsize/CXCR4-Antibody-Immunocytochemistry-Immunofluorescence-NB100-74396-img0003.jpg)
![Immunohistochemistry: CXCR4 Antibody [NB100-74396] - Immunostaining of CXCR4 in human cervical carcinoma tissue sections.](http://images.novusbio.com/fullsize/CXCR4-Antibody-Immunohistochemistry-NB100-74396-img0006.jpg)
![Immunocytochemistry/ Immunofluorescence: CXCR4 Antibody [NB100-74396] - The A2AR & baicalin attenuated CXCR4 expression in the hypoxia-induced PAH mouse model. CXCR4 & MYH11 expression levels in mouse PASMCs were analyzed by immunofluorescence staining (a; n = 3). CXCR4 protein is stained red, & MYH11 is stained green to indicate the PASMCs (×400; scale bars indicate 50 μm). CXCR4 fluorescence intensity was calculated (b; n = 3). CXCR4 protein expression levels in lung tissue were examined by western blot. GAPDH served as an internal control (c, d; n = 3). Data are presented as the mean ± SD. #Value significantly greater than the corresponding value in saline-treated normoxic mice (##P 50 CTCs/ 2.5 ml blood) was processed via ficoll density centrifugation & the PBMC fraction was collected. Immunomagnetic anti-CD45 depletion was performed on the obtained PBMCs & the remaining cells were washed, cytospunned onto the slides. Slides were stained for PSMA, EpCAM, sLex, & CXCR4 using the protocol as described in Figure S1. MDA, PC3, & KG1 cells were simultaneously stained as a control for the following markers: PSMA= Magenta, EpCAM= Yellow, HECA-452= Green, CXCR4= Red. All prostate CTCs expressed CXCR4, while, sLex expression was variable. The analysis of sLex intensity is shown in Figure 4. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24386459), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-74396_rabbit-polyclonal-cxcr4-antibody-31020241682122.jpg)
![Simple Western: 15-PGDH/HPGD Antibody [NB200-179] - Simple Western lane view shows a specific band for 15-PGDH/HPGD in 0.5 mg/ml of Lovo (left) and HeLa (right) lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/15-PGDH-HPGD-Antibody-Simple-Western-NB200-179-img0005.jpg "Simple Western: 15-PGDH/HPGD Antibody [NB200-179] - Simple Western lane view shows a specific band for 15-PGDH/HPGD in 0.5 mg/ml of Lovo (left) and HeLa (right) lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.")
![Immunohistochemistry: 15-PGDH/HPGD Antibody [NB200-179] - Expression of 15-prostaglandin dehydrogenase (15-PGDH) in healthy and inflamed synovial tissue. Immunohistochemical staining reveals positive (brown) staining for 15-PGDH (hematoxilin counterstained) in synovial tissue from healthy individuals (a) and patients with rheumatoid arthritis (b), osteoarthritis (c), or psoriatic arthritis (d). Original magnifications: x250 (a, b), x100 (c, d). Image collected and cropped by CiteAb from the following publication (//arthritis-research.biomedcentral.com/articles/10.1186/ar3851), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/15-PGDH-HPGD-Antibody-Immunohistochemistry-NB200-179-img0015.jpg)
![Immunohistochemistry: 15-PGDH/HPGD Antibody [NB200-179] - Cellular localization of 15-prostaglandin dehydrogenase (15-PGDH/HPGD) in rheumatoid arthritis synovial tissue and the effects of anti-rheumatic treatment on its expression. Double-immunofluorescence images show staining for 15-PGDH/HPGD-positive (red) cells and cell marker staining (green) for macrophage CD163, fibroblast prolyl-4-hydroxylase, and endothelial cell CD31. Merged images display double-stained cells in yellow. Original magnification: x400. Image collected and cropped by CiteAb from the following publication (//arthritis-research.biomedcentral.com/articles/10.1186/ar3851), licensed under a CC-BY license](http://images.novusbio.com/fullsize/15-PGDH-HPGD-Antibody-Immunohistochemistry-NB200-179-img0016.jpg)
![Western Blot: 15-PGDH/HPGD Antibody [NB200-179] - Western blot analysis of 15-PGDH in Lovo cell lysate.](http://images.novusbio.com/fullsize/15-PGDH-HPGD-Antibody-Western-Blot-NB200-179-img0001.jpg)
![Immunocytochemistry/Immunofluorescence: 15-PGDH/HPGD Antibody [NB200-179] - Confocal microscopy immunofluorescence images showing the expression of 15-PGDH (in green; antibody dilution, 1:200; DAPI in blue) after 24 h of stimulation with LTC4 in Caco-2 cells. The objective used was 63x. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28402256/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/15-PGDH-HPGD-Antibody-Immunocytochemistry-Immunofluorescence-NB200-179-img0017.jpg)
![Immunocytochemistry/Immunofluorescence: 15-PGDH/HPGD Antibody [NB200-179] - 15-PGDH antibody was tested in HeLa cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/15-PGDH-HPGD-Antibody-Immunocytochemistry-Immunofluorescence-NB200-179-img0004.jpg)
![Immunohistochemistry-Paraffin: 15-PGDH/HPGD Antibody [NB200-179] - IHC analysis of 15-PGDH in human synovial tissue from patient with rheumatoid arthritis . Image courtesy of an anonymous customer review.](http://images.novusbio.com/fullsize/15-PGDH-HPGD-Antibody-Immunohistochemistry-Paraffin-NB200-179-img0003.jpg)
![Immunohistochemistry: 15-PGDH/HPGD Antibody [NB200-179] - Staining in human fetal membrane tissue. Image from verified customer review.](http://images.novusbio.com/fullsize/15-PGDH-HPGD-Antibody-Immunohistochemistry-NB200-179-img0009.jpg)
![<b>Biological Strategies Validation and Genetic Strategies Validation.</b>Western Blot: 15-PGDH/HPGD Antibody [NB200-179] - A representative western blot and densitometric analysis of LTC4-induced SI protein expression after transfection with a scrambled control siRNA or 15-PGDH siRNA in HT-29 cells are shown. The cells were treated with or without 40 nM LTC4 for 48 h, and the change in the SI protein level was detected using an SI-specific antibody (1:1000 dilution) and 15-PGDH was detected using a 15-PGDH antibody (1:5000 dilution). The membrane was re-probed with an antibody against beta-actin to ensure equal loading. Statistical analysis was conducted using an unpaired t-test; *P=0.05, **P<0.01. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28402256/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/15-PGDH-HPGD Antibody-Knockdown Validated-NB200-179-img0018.jpg)
![Immunohistochemistry: 15-PGDH/HPGD Antibody [NB200-179] - Expression of 15-prostaglandin dehydrogenase (15-PGDH) in healthy & inflamed synovial tissue. Immunohistochemical staining reveals positive (brown) staining for 15-PGDH (hematoxilin counterstained) in synovial tissue from healthy individuals (a) & patients with rheumatoid arthritis (b), osteoarthritis (c), or psoriatic arthritis (d). Original magnifications: ×250 (a, b), ×100 (c, d). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/22616846), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-179_rabbit-polyclonal-15-pgdh-hpgd-antibody-310202415291984.jpg)
![Immunohistochemistry: 15-PGDH/HPGD Antibody [NB200-179] - Expression of 15-prostaglandin dehydrogenase (15-PGDH) in healthy & inflamed synovial tissue. Immunohistochemical staining reveals positive (brown) staining for 15-PGDH (hematoxilin counterstained) in synovial tissue from healthy individuals (a) & patients with rheumatoid arthritis (b), osteoarthritis (c), or psoriatic arthritis (d). Original magnifications: ×250 (a, b), ×100 (c, d). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/22616846), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-179_rabbit-polyclonal-15-pgdh-hpgd-antibody-310202415384117.jpg)
![Immunohistochemistry: 15-PGDH/HPGD Antibody [NB200-179] - Expression of 15-prostaglandin dehydrogenase (15-PGDH) in healthy & inflamed synovial tissue. Immunohistochemical staining reveals positive (brown) staining for 15-PGDH (hematoxilin counterstained) in synovial tissue from healthy individuals (a) & patients with rheumatoid arthritis (b), osteoarthritis (c), or psoriatic arthritis (d). Original magnifications: ×250 (a, b), ×100 (c, d). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/22616846), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-179_rabbit-polyclonal-15-pgdh-hpgd-antibody-31020241539722.jpg)
![Immunohistochemistry: 15-PGDH/HPGD Antibody [NB200-179] - Expression of 15-prostaglandin dehydrogenase (15-PGDH) in healthy & inflamed synovial tissue. Immunohistochemical staining reveals positive (brown) staining for 15-PGDH (hematoxilin counterstained) in synovial tissue from healthy individuals (a) & patients with rheumatoid arthritis (b), osteoarthritis (c), or psoriatic arthritis (d). Original magnifications: ×250 (a, b), ×100 (c, d). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/22616846), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-179_rabbit-polyclonal-15-pgdh-hpgd-antibody-310202415291976.jpg)
![Immunocytochemistry/ Immunofluorescence: 15-PGDH/HPGD Antibody [NB200-179] - Cellular localization of 15-prostaglandin dehydrogenase (15-PGDH) in rheumatoid arthritis synovial tissue & the effects of anti-rheumatic treatment on its expression. (a) Double-immunofluorescence images show staining for 15-PGDH-positive (red) cells & cell marker staining (green) for macrophage CD163, fibroblast prolyl-4-hydroxylase, & endothelial cell CD31. Merged images display double-stained cells in yellow. Original magnification: ×400. Light microscopy pictures of representative synovial biopsy sections show immunohistochemical positive (brown) staining for 15-PGDH before & after intra-articular treatment with glucocorticoids (b) & before & 8 weeks after initiation of methotrexate therapy (c) (hematoxilin counterstained). Graphs display the comparative 15-PGDH expression in rheumatoid arthritis synovial tissue before & after treatment with glucocorticoids or methotrexate as a percentage of the positive stained area versus the total tissue area. GC, glucocorticoids; Mtx, methotrexate. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/22616846), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-179_rabbit-polyclonal-15-pgdh-hpgd-antibody-31020241621232.jpg)
![Western Blot: 15-PGDH/HPGD Antibody [NB200-179] - Effect of LTC4 on 15-PGDH expression in the colon cancer cell line Caco-2(A) Quantification by qPCR of the mRNA expression of 15-PGDH following treatment with 40 nM LTC4 for 48 h in the presence or absence of AP100984 (a CysLT2 receptor antagonist, 1 μM) & JNK inhibitor I (10 μM). (B) Western blot showing 15-PGDH expression (antibody dilution, 1:5000) & densitometric analysis of LTC4-induced 15-PGDH up-regulation before or after the cells were stimulated with 40 nM LTC4 in the presence or absence of AP100984 & JNK inhibitor I for 48 h. (C) Confocal microscopy immunofluorescence images showing the expression of 15-PGDH (in green; antibody dilution, 1:200; DAPI in blue) after 24 h of stimulation with LTC4 in Caco-2 cells. The objective used was 63x. The data are presented as the percent of untreated control cells & represent the mean ± SEM of at least three separate experiments. Statistical analysis was conducted using an unpaired t-test; *P≤0.05, **P<0.01, ***P<0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28402256), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-179_rabbit-polyclonal-15-pgdh-hpgd-antibody-310202416205174.jpg)
![Western Blot: 15-PGDH/HPGD Antibody [NB200-179] - Effect of 15-PGDH down-regulation on the cell differentiation markers SI & Mucin-2(A) A representative western blot & densitometric analysis of LTC4-induced SI protein expression after transfection with a scrambled control siRNA or 15-PGDH siRNA in HT-29 cells are shown. The cells were treated with or without 40 nM LTC4 for 48 h, & the change in the SI protein level was detected using an SI-specific antibody (1:1000 dilution) & 15-PGDH was detected using a 15-PGDH antibody (1:5000 dilution). The membrane was re-probed with an antibody against beta –actin to ensure equal loading. (B) A representative western blot & densitometric analysis performed as in (A) shown here for Caco-2 cells. (C, D) Representative confocal microscopy immunofluorescence images from cells transfected with a scrambled control siRNA or 15-PGDH siRNA with or without stimulation with 40 nM LTC4 for 48 h. The expression of Mucin-2 (in red; antibody dilution, 1:500; DAPI in blue, dilution 1:1000) (C) in HT-29 cells & (D) Caco-2 cells is shown. The objective used was 63x, & the scale bar is 50 μm. The data are presented as the percent of control cells & represent the mean ± SEM of at least three separate experiments. Statistical analysis was conducted using an unpaired t-test; *P≤0.05, **P<0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28402256), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-179_rabbit-polyclonal-15-pgdh-hpgd-antibody-310202416212329.jpg)
![Immunohistochemistry: 15-PGDH/HPGD Antibody [NB200-179] - Cellular localization of 15-prostaglandin dehydrogenase (15-PGDH) in rheumatoid arthritis synovial tissue & the effects of anti-rheumatic treatment on its expression. (a) Double-immunofluorescence images show staining for 15-PGDH-positive (red) cells & cell marker staining (green) for macrophage CD163, fibroblast prolyl-4-hydroxylase, & endothelial cell CD31. Merged images display double-stained cells in yellow. Original magnification: ×400. Light microscopy pictures of representative synovial biopsy sections show immunohistochemical positive (brown) staining for 15-PGDH before & after intra-articular treatment with glucocorticoids (b) & before & 8 weeks after initiation of methotrexate therapy (c) (hematoxilin counterstained). Graphs display the comparative 15-PGDH expression in rheumatoid arthritis synovial tissue before & after treatment with glucocorticoids or methotrexate as a percentage of the positive stained area versus the total tissue area. GC, glucocorticoids; Mtx, methotrexate. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/22616846), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-179_rabbit-polyclonal-15-pgdh-hpgd-antibody-310202416205129.jpg)